These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22140023)

  • 1. The overlooked difference between human endogenous and recombinant erythropoietins and its implication for sports drug testing and pharmaceutical drug design.
    Reichel C
    Drug Test Anal; 2011; 3(11-12):883-91. PubMed ID: 22140023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control.
    Reichel C; Kulovics R; Jordan V; Watzinger M; Geisendorfer T
    Drug Test Anal; 2009 Jan; 1(1):43-50. PubMed ID: 20355158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desialylation improves the detection of recombinant erythropoietins in urine samples analyzed by SDS-PAGE.
    Desharnais P; Naud JF; Ayotte C
    Drug Test Anal; 2013; 5(11-12):870-6. PubMed ID: 23720238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of EPO-Fc fusion protein in human blood: screening and confirmation protocols for sports drug testing.
    Reichel C; Thevis M
    Drug Test Anal; 2012 Nov; 4(11):818-29. PubMed ID: 22764129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of intact recombinant human erythropoietins applied in doping by means of planar gel electrophoretic techniques and matrix-assisted laser desorption/ionisation linear time-of-flight mass spectrometry.
    Stübiger G; Marchetti M; Nagano M; Reichel C; Gmeiner G; Allmaier G
    Rapid Commun Mass Spectrom; 2005; 19(5):728-42. PubMed ID: 15700237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of AMGEN clone 9G8A anti-Epo antibody for application in doping control.
    Reichel C; Benetka W; Lorenc B; Thevis M
    Drug Test Anal; 2016 Nov; 8(11-12):1131-1137. PubMed ID: 27552163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycosylation characterization of recombinant human erythropoietin produced in glycoengineered Pichia pastoris by mass spectrometry.
    Gong B; Burnina I; Stadheim TA; Li H
    J Mass Spectrom; 2013 Dec; 48(12):1308-17. PubMed ID: 24338886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin.
    Skibeli V; Nissen-Lie G; Torjesen P
    Blood; 2001 Dec; 98(13):3626-34. PubMed ID: 11739166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in sialic acid O-acetylation between human urinary and recombinant erythropoietins: a possible mass spectrometric marker for doping control.
    Reichel C
    Drug Test Anal; 2013; 5(11-12):877-89. PubMed ID: 24353190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interference of heparin on IEF-PAGE of erythropoietins.
    Reichel C; Benetka E; Geisendorfer T; Scheiblhofer V; Abzieher F
    Drug Test Anal; 2010; 2(11-12):568-75. PubMed ID: 21204288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc-fragment removal allows the EPO-Fc fusion protein to be detected in blood samples by IEF-PAGE.
    Postnikov P; Krotov G; Mesonzhnik N; Efimova Y; Rodchenkov G
    Drug Test Anal; 2015; 7(11-12):999-1008. PubMed ID: 26695487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-dimensional electrophoresis of recombinant human erythropoietin: a future method for the European Pharmacopoeia?
    Schlags W; Lachmann B; Walther M; Kratzel M; Noe CR
    Proteomics; 2002 Jun; 2(6):679-82. PubMed ID: 12112848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications and biomonitoring issues of recombinant erythropoietins for doping control.
    Tsitsimpikou C; Kouretas D; Tsarouhas K; Fitch K; Spandidos DA; Tsatsakis A
    Ther Drug Monit; 2011 Feb; 33(1):3-13. PubMed ID: 21099742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights for identification of doping with recombinant human erythropoietin micro-doses after high hydration.
    Martin L; Ashenden M; Bejder J; Hoffmann M; Nordsborg N; Karstoft K; Morkeberg J; Sharpe K; Lasne F; Marchand A
    Drug Test Anal; 2016 Nov; 8(11-12):1119-1130. PubMed ID: 27390252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous application.
    Okano M; Sato M; Kaneko E; Kageyama S
    Drug Test Anal; 2011; 3(11-12):798-805. PubMed ID: 22012825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practicing IEF-PAGE of EPO: the impact of detergents and sample application methods on analytical performance in doping control.
    Reichel C
    Drug Test Anal; 2010; 2(11-12):603-19. PubMed ID: 21204292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An optimized SDS-PAGE protocol with a new blotting system for the initial testing procedure of ESAs in doping control.
    Martin L; Martin JA; Audran M; Marchand A
    Drug Test Anal; 2022 Jan; 14(1):181-187. PubMed ID: 33269539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin and erythropoiesis stimulating agents.
    Debeljak N; Sytkowski AJ
    Drug Test Anal; 2012 Nov; 4(11):805-12. PubMed ID: 22508651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing for recombinant erythropoietin.
    Delanghe JR; Bollen M; Beullens M
    Am J Hematol; 2008 Mar; 83(3):237-41. PubMed ID: 17918255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARCOSYL-PAGE: a new method for the detection of MIRCERA- and EPO-doping in blood.
    Reichel C; Abzieher F; Geisendorfer T
    Drug Test Anal; 2009 Nov; 1(11-12):494-504. PubMed ID: 20355164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.